AC Immune And Takeda Sign Exclusive Option And License Agreement For Active Immunotherapy Targeting Amyloid Beta For Alzheimer’s Disease

Takeda and AC Immune SA announced a worldwide option and license agreement for AC Immune’s active immunotherapies targeting toxic forms of amyloid beta, including ACI-24.060 for the treatment of Alzheimer’s disease.